Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) as biomarkers for poor outcome Hodgkin lymphoma patients

Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) as biomarkers for poor outcome Hodgkin lymphoma patients

US Patent 9506118 · Granted Nov 29, 2016

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Microfluidic diagnostic assembly2021
Serine proteases as biomarkers for ovarian cancer2020
Method for treating skin cancer using radiation therapy2019